Oestrogen receptor-beta expression in melanocytic lesions

Area of Science:

• Dermatology
• Oncology
• Endocrinology

Background:

• Melanoma incidence and mortality show demographic variations.
• Early research on estrogen receptor alpha (ERalpha) suggested no significant role in melanocytic lesion pathophysiology.
• The discovery of estrogen receptor beta (ERbeta) prompted re-evaluation of estrogen's role in melanoma.

Purpose of the Study:

• To investigate the differential expression patterns of ERalpha and ERbeta in various benign and malignant melanocytic lesions.
• To correlate ERbeta expression with lesion characteristics, including atypia, invasion depth, and tumor microenvironment.

Main Methods:

• Immunohistochemical staining for ERalpha and ERbeta was performed on a spectrum of melanocytic lesions.
• Lesions included benign nevocytic nevi, dysplastic nevi (mild, moderate, severe atypia), lentigo malignas, and melanomas (varying Clark depth and Breslow thickness).

Main Results:

• ERbeta was the predominant estrogen receptor identified in all studied melanocytic lesions, whereas ERalpha was not significant.
• Intense ERbeta immunostaining was observed in severe dysplastic nevi and lentigo malignas.
• ERbeta expression levels demonstrated a correlation with the tumor microenvironment and increasing invasion depth, from keratinocyte proximity to thick melanomas.

Conclusions:

• ERbeta expression is significantly associated with melanocytic neoplasia and progression.
• The varying ERbeta expression relative to the tumor microenvironment and invasion depth indicates its potential utility.
• ERbeta may serve as a valuable surrogate marker for assessing neoplasia and predicting prognosis in malignant melanoma.